It's fascinating how the human body can surprise us with its complexities, and sometimes, with conditions that are truly rare. One such condition is epithelioid hemangioendothelioma (EHE), a term that might sound daunting but describes a unique type of tumor originating from the cells lining our blood vessels.
First described by Weiss and Enzinger back in 1982, EHE is often characterized as a 'borderline' tumor. This means its biological behavior sits somewhere between a benign hemangioma (a non-cancerous tumor of blood vessels) and a malignant angiosarcoma (a more aggressive blood vessel cancer). The unpredictable nature of EHE is one of its defining features, with a global incidence estimated to be less than one in a million. It tends to affect adults, often between their 30s and 40s, with a slightly higher prevalence in women.
When we delve into the pathology, EHE is noted for its characteristic growth pattern. The tumor cells tend to infiltrate along the liver sinusoids, which are small blood channels within the liver. These cells themselves have an 'epithelioid' appearance, meaning they resemble epithelial cells, but they are fundamentally of endothelial origin. For diagnosis, a key step involves immunohistochemistry, where markers like CD34, CD31, and Factor VIII are typically positive, acting as a gold standard for confirmation.
Clinically, symptoms can vary. In the liver, for instance, patients might experience pain in the upper right abdomen, enlargement of the liver and spleen, and unexplained weight loss. Jaundice can occur in about 20% of cases. Imaging techniques like CT scans can offer clues, sometimes showing a distinctive 'capsular retraction sign' or a 'halo sign.' However, the definitive diagnosis always hinges on examining a liver biopsy under a microscope.
Treatment strategies are tailored to the stage of the disease. For localized disease, surgical resection might be an option. For more widespread or multifocal EHE, liver transplantation has shown promising results, with survival rates of 54.5% to 79.5% at five years for multifocal cases. Even in cases where the cancer has spread outside the liver, a five-year survival rate of around 74.4% has been reported after transplantation. Minimally invasive techniques, like staged ablation, have also been employed successfully for diffuse lesions, with patients showing recovery of liver function post-procedure.
It's important to note that EHE isn't confined to the liver. It can appear in other organs too, such as the lungs, bones, and soft tissues. Pulmonary EHE, for example, is a rare form that progresses slowly, potentially leading to restrictive lung function issues over many years. The underlying cause of EHE remains largely unknown, and its connection to autoimmune conditions is not yet confirmed.
One of the challenges with EHE is its potential for misdiagnosis. Because it can present as multiple lesions in the liver or lungs, it's often mistaken for metastatic cancer. This underscores the critical role of precise pathological examination and specialized immunohistochemical markers, and increasingly, genetic analysis (like WWTR1-CAMTA1, YAP1-TFE3 gene fusions) for definitive diagnosis, especially when distinguishing it from angiosarcoma.
While the prognosis can be unpredictable, influenced by factors like invasion of major blood vessels or lymph node involvement, ongoing research and evolving treatment approaches offer hope. The journey of understanding and managing EHE is a testament to the continuous advancements in medical science, aiming to provide better outcomes for those affected by this rare condition.
